Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Period Ended March 31, 2025" Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.

Press release · 05/21 07:38

Based on the provided financial report articles, I generated the title for the article: "Quarterly Report for the Period Ended March 31, 2025" Please note that the title may not be exact, as the provided text appears to be a financial report with various sections and data, and the title may not be explicitly stated.

The financial report presents the financial statements of the company for the quarter ended March 31, 2025. The company reported a net loss of $X million, with total revenues of $Y million and total expenses of $Z million. The company’s cash and cash equivalents decreased by $X million to $Y million, and its accounts payable and accrued liabilities increased by $X million to $Y million. The company’s convertible notes payable decreased by $X million to $Y million. The company’s fair value measurements were primarily Level 1 and Level 2, with no Level 3 measurements. The company’s related party transactions included a loan from Pharmacy No. 27 Ltd. and a convertible note payable to the same entity. The company’s non-related party transactions included sales and purchases of goods and services. The company’s website and computer equipment and software were recorded as assets, and its furniture and fixtures were recorded as property, plant, and equipment.

Overview

Balance Labs, Inc. is a consulting firm that provides business development and consulting services to start-up and development-stage companies. The company was incorporated in 2014 and is based in the United States. Balance Labs’ business model is to provide customized consulting services to help businesses improve their operations, sales and marketing plans, and introduce them to experienced professionals who can contribute to their success.

Financial Performance

For the three months ended March 31, 2025, Balance Labs reported a net loss of $6,406, a significant improvement from the $116,943 net loss in the same period in 2024. This 95% decrease was primarily due to the cancellation of an accounts payable balance by one of the company’s vendors during the first quarter of 2025.

Key financial metrics:

Metric	March 31, 2025	March 31, 2024
Net Loss	$6,406	$116,943
General & Administrative Expenses	$4,262	$4,040
Professional Fees	$25,035	$16,000
Other Income (Expense)	$72,433	$(51,225)
Unrealized Gain on Securities	$1,594	$5,687
Cash	$3,040	$13,199
Working Capital (Deficiency)	$(5,077,512)	$(5,071,106)

The company’s liquidity position remains a concern, with a working capital deficiency of over $5 million as of March 31, 2025. Balance Labs used $22,659 in cash for operating activities during the first quarter of 2025, an improvement from the $37,045 used in the same period in 2024.

Strengths and Weaknesses

Strengths:

Experienced in providing customized consulting services to start-ups and development-stage companies
Ability to introduce clients to valuable professional contacts
Reduction in net loss and improvement in cash flow in Q1 2025

Weaknesses:

Limited client base, with only three clients since inception
Significant working capital deficiency and going concern uncertainty
Reliance on vendor concessions and other one-time events to improve financial performance

Outlook

Balance Labs’ future outlook remains uncertain due to its ongoing liquidity challenges and going concern issues. The company is actively pursuing new client relationships, but its lack of a diversified client base means it may continue to experience temporary imbalances between cash receipts and operating expenses.

To address its financial situation, Balance Labs is working to manage its current liabilities and make changes to its operations to improve cash flow and liquidity. However, the company may need to obtain additional financing to fund its operations, which could come with restrictions or lead to substantial dilution for shareholders.

Overall, Balance Labs faces significant hurdles in achieving long-term financial stability and growth. The company’s ability to continue as a going concern will depend on its success in securing new clients, managing costs, and obtaining the necessary financing to support its operations.